It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s disease (PD) is a progressive chronic neurodegenerative condition characterized by the loss of dopaminergic neurons within the substantia nigra. Current PD therapeutic strategies are mainly symptomatic and can lead to motor complications overtime. As a result, alternative medicine may provide an effective adjuvant treatment for PD as an addition to or as a replacement of the conventional therapies. The aim of this work was to evaluate the effects of Bee Venom (BV) and dopamine (DA)-loaded nanoparticles in a reserpine-induced animal model of PD. After inducing PD with reserpine injection, different groups of male rats were treated with L-Dopa, BV, DA-nanoparticles. Our findings showed that BV and DA-nanoparticles administration restored monoamines, balanced glutamate/GABA levels, halted DNA fragmentation, decreased pro-inflammatory mediators (IL-1β and TNF-α), and elevated anti-inflammatory mediators (PON1) and neurotropic factor (BDNF) levels in comparison with conventional therapy of PD. Furthermore, in a reserpine-induced PD rat model, the ameliorative effects of BV were significantly superior to that of DA-nanoparticles. These findings imply that BV and DA-nanoparticles could be useful as adjuvant treatments for PD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 National Organization for Drug Control and Research (NODCAR), Physiology Department, Giza, Egypt (GRID:grid.419698.b)
2 Cairo University, Biochemistry Department, Faculty of Pharmacy, Giza, Egypt (GRID:grid.7776.1) (ISNI:0000 0004 0639 9286)
3 Helwan University, Pathology Department, Faculty of Medicine, Helwan, Egypt (GRID:grid.412093.d) (ISNI:0000 0000 9853 2750)
4 NODCAR, Analytical and Inorganic Chemistry Department, Giza, Egypt (GRID:grid.419698.b)
5 Beni-Suef University, Medical Physiology Department, Faculty of Medicine, Beni-Suef, Egypt (GRID:grid.411662.6) (ISNI:0000 0004 0412 4932)
6 Dar Al Uloom University, Basic Medical Sciences Department, College of Medicine, Riyadh, Kingdom of Saudi Arabia (GRID:grid.449023.8) (ISNI:0000 0004 1771 7446); Menoufia University, Histology and Cell Biology Department, Faculty of Medicine, Shibin El Kom, Egypt (GRID:grid.411775.1) (ISNI:0000 0004 0621 4712)